Recent News

By Category: Policy & Initiatives

Chapel Hill drug firm Cempra lands bioterror antibiotic contract worth up to $58M

(WRAL) Cempra (Nasdaq: CEMP) has won a contract worth as much as $58 million over five years from the Biomedical Advanced Research and Development Authority (BARDA) for development of an antibiotic that could be used by young people and to counter bioterror threats. The company has secured a two-year deal worth $17 million to work Read More »

May 28, 2013
| Filed under North America, Biological Weapons, Countermeasures, International, Policy & Initiatives, and Research
Share

Reports of PED in the U.S. Prompt Calls for Steped Up Biosecurity

(Farmscape) The Canadian Swine Health Board is advising Canadian pork producers to step up their focus on biosecurity in the wake of reports of possible outbreaks of Porcine Epidemic Diarrhea in the U.S. Possible outbreaks of Porcine Epidemic Diarrhea, a viral disease that causes severe watery diarrhea in pigs resulting in high morbidity in sows Read More »

May 24, 2013
| Filed under North America, Agents & Toxins, Agriculture, and Policy & Initiatives
Share

Sen. Roberts: NBAF Construction Set To Begin

(KCUR) Senator Pat Roberts’ office says the official groundbreaking for the National Bio and Agro Defense Facility will take place next Tuesday, May 28, on the site in Manhattan. The first phase of the project is to construct a utility plant and emergency power capacity dedicated to the top security labs.The $1.2 billion dollar facility Read More »

May 24, 2013
| Filed under Biological Weapons, Biosafety, Countermeasures, Policy & Initiatives, Public Health, and Research
Share

Anthrax drug brings $334 million to Pentagon advisor’s biotech firm

(TimesRecordNews) Over the last decade, former Navy Secretary Richard J. Danzig, a prominent lawyer, presidential advisor and biowarfare consultant to the Pentagon and the Department of Homeland Security, has urged the government to counter what he called a major threat to national security. Terrorists, he warned, could easily engineer a devastating killer germ: a form Read More »

May 24, 2013
| Filed under North America, Policy & Initiatives, and Research
Share

BARDA Partners with GSK for Hospital and Biothreat Antibacterials

(GlobalBiodefense) The U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has entered into a collaborative agreement with Glaxo Smith Kline (GSK) to evaluate the efficacy and safety of the company’s portfolio of clinical stage antibacterial assets for treating hospital and biothreat infections. The contract is unique in that it Read More »